北京若生智能科技有限公司
Drug Database
BE

benfotiamine + folic acid + benzamine (Zycose)

✓ Approved

Zylera · 小分子 · 小分子

什么是 benfotiamine + folic acid + benzamine？

benfotiamine + folic acid + benzamine 是一种小分子，由Zylera研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

商品名Zycose
公司Zylera
药物类别小分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Zylera

治疗适应症

benfotiamine + folic acid + benzamine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
InvestigationsGlucose tolerance test abnormal✓ Approved

相关研究文献

PubMedEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2026-09-10

Ferrous Sulfate and Folic Acid Supplementation in Pregnant People in Primary Health Care: a Cross-Sectional Study, Criciúma, 2022.

Campos-Rosa Jhonatan J, Puchivailo Ricardo Augusto Cardoso RAC, Schäfer Antônio Augusto AA, Meller Fernanda de Oliveira FO et al.

To evaluate the prevalence and factors associated with supplementation of ferrous sulfate and folic acid in pregnant people. A cross-sectional, representative study with pregnant people treated in Primary Health Care in Criciúma, Santa Catarina, in 2023. Ferrous sulfate and folic acid supplements were evaluated based on the prenatal booklet for pregnant people. The prevalence of supplementation was calculated with their respective 95% confidence intervals (95%CI). Crude and adjusted Poisson regression analyses (hierarchical model) were performed, estimating prevalence ratios (PR) and their respective 95%CI, to verify the associated factors. A total of 428 pregnant people were interviewed. Of these, 97.4% used ferrous sulfate supplementation during pregnancy, and 93.7% folic acid. The analyses indicated that the use of ferrous sulfate was higher in older pregnant people, with PR 1.06 (95%CI 0.99; 1.13), and who consumed alcohol during pregnancy, with PR 1.04 (95%CI 1.00; 1.08). Regarding the use of folic acid, it was higher among pregnant people who had at least six prenatal visits, with PR 1.10 (95%CI 1.01; 1.20). The results indicate high iron and folic acid supplementation among pregnant people in Primary Health Care. The identification of associated factors can guide more targeted and effective intervention strategies by Health Management.

PMID 42718097
阅读全文 →
PubMedDrug design, development and therapy2026-09-10

Folic Acid Therapy is Associated with a Lower Risk of Incident Diabetes and Better Glycemic Status in Patients with Coronary Heart Disease: Findings from a Multicenter Propensity Score-Matched Analysis.

Song Shuaiwei S, Cai Xintian X, Li Xiyang X, Cui Penghui P et al.

Although elevated homocysteine has been consistently linked to cardiovascular disease development and progression, whether homocysteine-lowering therapy reduces diabetes risk and improves glycemic status in patients with coronary heart disease (CHD) remains unclear. This study investigated whether folic acid (FA) therapy and different treatment doses were associated with reduced new-onset diabetes risk and improved long-term glycemic control in CHD patients. The multicenter study used a propensity score-matched design. Patients with CHD were categorized as FA users or non-users, followed by 1:4 propensity score matching to minimize baseline imbalance, ultimately yielding 2440 patients for analysis. During a median follow‑up of 3.35 years, 510 incident cases of diabetes were recorded. Multivariable Cox regression models evaluated the associations of FA use and daily dose with diabetes risk. Kaplan-Meier curves compared cumulative diabetes risk between groups. Repeated glycated hemoglobin (HbA1c) measurements were used to assess long-term glycemic trajectories, and restricted cubic spline analysis examined the dose-response relationship between cumulative FA dose and diabetes risk. Multivariable Cox regression analyses showed that FA use was significantly associated with lower new-onset diabetes risk in CHD patients before and after matching (HR: 0.749; 95% CI:0.586-0.957; P=0.021). Dose-stratified analyses indicated that the 0.8 mg/day group had the greatest risk reduction and a more favorable long-term HbA1c trajectory (HR: 0.637; 95% CI:0.453-0.897; P=0.010). FA also showed a cumulative dosage effect, with risk-lowering benefits becoming more evident when cumulative dose exceeded 140 mg (HR: 0.478; 95% CI:0.351-0.650; P<0.001). FA use was significantly associated with reduced new-onset diabetes risk and improved long-term glycemic status in CHD patients, particularly at 0.8 mg/day and cumulative dose >140 mg. These findings suggest that FA may have a potential role in diabetes prevention among CHD patients, although this should be interpreted cautiously given the observational study design.

PMID 42719341
阅读全文 →
PubMedACS applied materials & interfaces2026-09-10

Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer.

Li Kaiming K, Zhu Xiaole X, Wu Haisi H, Li Jiang J et al.

Triple-negative breast cancer (TNBC) tends to exhibit extremely large rates of tumor recurrence and mortality owing to the absence on effective therapeutic targets. Paclitaxel is the chemotherapeutic drug of choice, but the clinical efficacy in TNBC is limited. In the present study, we developed a folic acid (FA)-modified red blood cell membrane biomimetic drug delivery system encapsulating both paclitaxel and artesunate (PA@LRM-FA) against TNBC, aimed at enhancing ferroptosis and promoting immunogenic cell death to improve paclitaxel efficacy. The morphology, particle size, zeta potential, particle stability, paclitaxel and artesunate loading capacity, and paclitaxel and artesunate encapsulation efficiency of the formulations were studied. Through a cellular assay, we discovered that PA@LRM-FA inhibited the 4T1 cell proliferation, induced ROS accumulation, and promoted ferroptosis and immunogenic cell death. In tumor-bearing mice, PA@LRM-FA effectively targeted tumor tissues for the delivery of paclitaxel and artesunate and significantly induced ferroptosis, promoting immunogenic cell death and active immune cells in 4T1 tumors, resulting in a marked inhibition of tumor growth. Taken together, this work demonstrated a feasible therapeutic approach to inhibit TNBC by enhancing tumor ferroptosis and immunogenic cell death through PA@LRM-FA delivery of paclitaxel and artesunate.

PMID 42717767
阅读全文 →
PubMedGeobiology2026-09-10

Origins of Improved Hardness in Bioinspired Aragonite Precipitated Under Simulated Biologic Conditions.

Chomhom Boontharee B, Farfan Gabriela A GA, Greeves Samantha S, Penkman Kirsty K et al.

Biogenic aragonite is a composite of mineral and biomolecules that exhibits superior material properties compared to its inorganic analog. This superiority underpins the success of the bioaragonite structures which support coral reefs and shell fisheries, yet the mechanisms improving the physical resilience of bioaragonite are not well understood. In this study, aragonite is synthesised under chemical conditions which simulate those of calcification sites in marine organisms. Aspartic acid, glutamic acid, and glycine in solution are incorporated into the aragonite at concentrations typically observed in marine biominerals and are observed to significantly improve aragonite Vickers hardness. Aspartic acid is incorporated more efficiently than glutamic acid or glycine, but for comparable amounts of amino acid incorporation, glycine improves aragonite hardness significantly more than either aspartic or glutamic acid. Glycine and glutamic acid incorporation reduce the aragonite grain size, thereby improving resilience to indentation via energy dissipation along grain boundaries. In contrast, aspartic acid also improves hardness on a smaller scale, possibly due to crystal structure distortions. These results suggest that amino acid incorporation influences biogenic aragonite hardness via multiple mechanisms and provide a prototype for exploring the influence of more complicated biomineral proteins.

PMID 42720183
阅读全文 →
PubMedThe AAPS journal2026-09-10

Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions.

Morse Bridget L BL, Han Bing B, Alberts Jeffrey J JJ, Posada Maria M MM et al.

Simvastatin is a commonly prescribed medication and a sensitive CYP3A4 substrate requiring dosage modification with CYP3A4 precipitants. Unlike other CYP3A4 substrates, grapefruit juice (GFJ) causes the largest increase in simvastatin exposure of any CYP3A4 inhibitor, leading to misunderstanding of simvastatin fraction escaping CYP3A4 metabolism in the gut (Fg, CYP3A4) and fraction metabolized by CYP3A4 in the liver (fm,CYP3A4). Simvastatin is a prodrug that is converted to the active simvastatin acid, though the mechanisms responsible for in vivo simvastatin acid formation are not well-understood. GFJ also decreases the simvastatin acid:simvastatin exposure ratio, suggesting inhibition of simvastatin acid formation. In the current work, we used a static approach to define simvastatin CYP3A4 parameters, using clinical data with index substrate midazolam; estimated simvastatin Fg,CYP3A4 and fm,CYP3A4 were ~ 0.4 and ~ 0.9, respectively. In vitro data assessing the stability of simvastatin and simvastatin acid demonstrated rapid conversion in gastric fluid that was highly pH-dependent. A simvastatin PBPK model was constructed incorporating these CYP3A4 parameters and simvastatin acid formation in stomach, intestine and plasma. The model reproduced the nonlinear pharmacokinetics of simvastatin and CYP3A4 precipitant effects, thus qualifying the model for prediction of CYP3A4-mediated interactions on both simvastatin and simvastatin acid. Simvastatin overall Fg was estimated as ~ 0.2, lower than the Fg,CYP3A4 due to additional intestinal esterase-mediated formation of simvastatin acid. The simvastatin-GFJ effect was explained by inhibition of this intestinal simvastatin acid formation, along with CYP3A4 inhibition. The unique effect of food on the simvastatin acid:simvastatin exposure ratio could also be replicated using this PBPK model.

PMID 42717157
阅读全文 →
PubMedFrontiers in microbiology2026-09-10

Topical compound acid peeling remodels scalp microbiota and lipid homeostasis in seborrheic dermatitis: a multi-omics study.

Zhang Hongyan H, Shi Yetan Y, Hu Lifang L

Current therapeutic options for scalp seborrheic dermatitis (SSD) remain suboptimal, highlighting the demand for more effective and safe treatment strategies. To investigate the efficacy and underlying mechanisms of a novel 7.5% five-acid compound formulation for the treatment of SSD. A total of 319 patients diagnosed with SSD at the dermatology outpatient clinic were enrolled. All patients received four sessions of scalp compound acid therapy and were included in efficacy and safety analyses. A subgroup of 30 male participants from the 319-patient cohort underwent scalp sampling before and after treatment for combined microbiomic and lipidomic detection. Meanwhile, 10 matched male SSD patients who did not received compound acid therapy were enrolled as the control group for multi-omics analyses. All 319 SSD patients presented marked relief of scalp erythema, scaling and pruritus after repeated compound acid treatment, with only 6 individuals experiencing temporary mild scalp irritation after the initial treatment. Integrated microbiomic and lipidomic analyses were restricted to a male subcohort (30 treated patients and 10 matched untreated male SSD controls). Within this male subgroup, the relative abundance of the genus Staphylococcus and the genus Malassezia were significantly lowered post-treatment. And the observed lipid alterations may be linked to changes in antioxidant response, inflammatory signaling and fatty acid metabolic pathways. Lipidomic profiling suggests that compound acid peeling may rebalance scalp lipid profiles, accompanied by elevated levels of barrier-protective antioxidant phosphatidylcholines, reduced pro-inflammatory oxidized fatty acids, and altered core fatty acid biosynthesis pathways. The topical scalp compound acid therapy effectively alleviates clinical symptoms in SSD patients and represents a promising novel therapeutic approach.

PMID 42718769
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多benfotiamine + folic acid + benzamine